Delving into the Latest Updates on Nuance Biotech, Inc. with Synapse

概览

疾病领域	数量

肿瘤	1

排名前五的药物类型	数量

化学药	1

排名前五的靶点	数量

Tubulin(微管蛋白)	1

关联

1

项与 Nuance Biotech, Inc. 相关的药物

SPR-064

靶点

Tubulin

作用机制

微管蛋白抑制剂 [+1]

在研机构

Sphaera Pharma Pvt Ltd. [+1]

原研机构

University of California, Davis

在研适应症

实体瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 Nuance Biotech, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Nuance Biotech, Inc. 相关的专利（医药）

登录后查看更多信息

1

项与 Nuance Biotech, Inc. 相关的文献（医药）

Nano Biomedicine and Engineering

New immunomodulatory targets and next generation active immune checkpoint control immunotherapy

作者: Ni, Jian

Despite the success of immunomodulatory antibodies in immuno-oncol., challenges remain in expanding the target space, developing next-generation immune checkpoint inhibitors and active immune checkpoint control immunotherapy with improved efficacy and safety, and addressing innate and acquired resistance to immunotherapy.This presentation focuses the leading immunomodulatory pathways as well as therapeutic targets we have identified in B7 superfamily members: B7-H1 (PDL1), B7-H2 (ICOSL), B7-H3 and B7-H4, TNF ligands and receptor superfamily: Blys (THANK), DR3 (TNFR25), DR4, DR5, DR6, GITR (AITR, TNFR18), GITRL, TR2, LIGHT, TR6, TL1A, RANK, TNFRSF19, RELT, TR1 (DcR3), DcR1and DcR2, Siglecs family: Siglec 5, 7, 8, 9, 10, 11, and Galectin family: Galectin 9, 10, 11, 12.

100 项与 Nuance Biotech, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Nuance Biotech, Inc. 相关的转化医学

登录后查看更多信息